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Prostate cancer and osteosarcoma are the second most common type of cancer 
affecting men and the fifth most common malignancy among adolescents, respectively. 
The use of non-toxic natural or natural-derived products has been one of the current 
strategies for cancer therapy, owing to the reduced risks of induced-chemoresistance 
development and the absence of secondary effects. In this perspective, lactoferrin (Lf), 
a natural protein derived from milk, emerges as a promising anticancer agent due to its 
well-recognized cytotoxicity and anti-metastatic activity. Here, we aimed to ascertain 
the potential activity of bovine Lf (bLf) against highly metastatic cancer cells. The bLf 
effect on prostate PC-3 and osteosarcoma MG-63 cell lines, both displaying plasma-
lemmal V-ATPase, was studied and compared with the breast cancer MDA-MB-231 
and the non-tumorigenic BJ-5ta cell lines. Cell proliferation, cell death, intracellular pH, 
lysosomal acidification, and extracellular acidification rate were evaluated. Results show 
that bLf inhibits proliferation, induces apoptosis, intracellular acidification, and perturbs 
lysosomal acidification only in highly metastatic cancer cell lines. By contrast, BJ-5ta 
cells are insensitive to bLf. Overall, our results establish a common mechanism of action 
of bLf against highly metastatic cancer cells exhibiting plasmalemmal V-ATPase. This 
study opens promising perspectives for further research on the anticancer role of Lf, 
which ultimately will contribute to its safer and more rational application in the human 
therapy of these life-threatening cancers.
Keywords: highly metastatic cancer cells, V-aTPase, bovine lactoferrin, cancer therapy, intracellular ph, lysosomal 
dysfunction
inTrODUcTiOn
Cancer is currently one the most lethal diseases worldwide, and metastases are the main cause of 
cancer-associated mortality. The urge to develop more targeted and efficient cancer therapies is 
therefore a current challenge (1). A recent study showed that the prostate cancer is one of the most 
frequently diagnosed cancers, being the second most common in men with incidence rates of 1.1 
million (1). Also, despite its rarity, osteosarcoma is the most common primary bone malignancy 
Abbreviations: BafA1, bafilomycin A1; BCECF-AM, 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein-acetoxymethyl 
ester; bLf, bovine lactoferrin; CF, carboxyfluorescein; CFSE, carboxyfluorescein diacetate succinimidyl ester; ConcA, concana-
mycin A; ECAR, extracellular acidification rate; Lf, lactoferrin; pHi, intracellular pH; PS, phosphatidylserine.
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in children and adolescents, and the fifth most common malig-
nancy among adolescents and young aged (2, 3). Currently, the 
development of cancer therapy strategies based on the exploita-
tion of different anticancer drugs, especially non-toxic natural or 
natural-derived products, has been subject of particular interest 
(4, 5). Among the different natural compounds with anticancer 
activities, some milk compounds and/or milk-derived bioactive 
peptides have been identified as potential agents for cancer 
prevention (6, 7). In particular, lactoferrin (Lf) is a natural iron-
binding glycoprotein that was first identified in bovine milk. It 
is synthesized by mucosal epithelial cells and neutrophils dur-
ing inflammatory processes and is present in many tissues and 
body fluids of mammals. Lf exhibits multiple biological effects, 
including anticancer and anti-metastatic activities against a wide 
range of human cancers (8–10). Lf from bovine milk [bovine 
lactoferrin (bLf)], which exhibits the same biological properties 
as the human Lf, is not only cheaply produced compared with 
other sources but is also commercially available and well tolerated 
after ingestion (11). Altogether, these properties confer to bLf the 
requirements of an ideal nutraceutical. In fact, the European Food 
Safety Authority has approved bLf as a safe ingredient for various 
applications (12). Interestingly, in vitro and in vivo studies, as well 
as clinical trials have been conducted to evaluate the effectiveness, 
safety, and tolerability of Lf in the treatment of metastatic cancers 
(13, 14). For instance, orally administered recombinant human Lf 
was well tolerated and displayed anticancer activity against solid 
tumors like non-small cell lung cancer and renal cell carcinoma, 
without secondary effects (13, 14).
Recent research has provided mechanistic insights on the 
anticancer activity of Lf based on its ability to interfere with cell 
cycle progression and to induce apoptosis (15, 16), as well as on its 
anti-metastatic (9, 17), anti-angiogenic (18), and immunostimu-
latory potential (19), and its iron sequestration capacity (20). 
Despite this knowledge, the molecular targets of Lf underlying its 
selective activity against cancer cells were until recently unknown.
However, we identified V-ATPase as a bLf target (21). V-ATPase 
is an ATP-driven proton pump that is normally present in the 
intracellular compartments (22) but, in highly metastatic cancer 
cells, it is also present at the plasma membrane and is responsible 
for the generation of an acidic tumor microenvironment, playing 
pivotal roles in tumor invasion and metastasis (23–25). In fact, 
previous studies showed that highly metastatic breast cancer cells 
express higher levels of V-ATPase, mainly localized at the plasma 
membrane, than poorly metastatic cancer cells, which display a 
predominant intracellular localization (23).
In our study, we assessed the sensitivity of breast cell lines 
with different metastatic potentials to bLf and showed that bLf 
exhibits preferential cytotoxicity against the highly metastatic 
cancer cell lines Hs 578T and MDA-MB-231, which display 
V-ATPase at the plasma membrane (21). These results supported 
the notion also reported by others (26) that this proton pump 
is an attractive target in the therapy of metastatic cancers and a 
promising candidate for anticancer drugs such as bLf.
Herein, we investigated the potential of bLf in the treatment 
of prostate cancer and osteosarcoma. To this end, we assessed 
its effect on cell proliferation and cell death in prostate PC-3 
and osteosarcoma MG-63 highly metastatic cell lines, both 
reported to display V-ATPase at the plasma membrane (23–25), 
and compared it with the breast cancer MDA-MB-231 and the 
non-tumorigenic fibroblast BJ-5ta cell lines. Besides the effect 
of bLf on the intracellular pH (pHi), lysosomal acidification and 
extracellular acidification rate (ECAR), we also evaluated a pos-
sible relation between cell sensitivity and the V-ATPase protein 
levels in the four cell lines.
MaTerials anD MeThODs
chemical and solutions
Bovine lactoferrin was obtained from DMV (Veghel, The 
Netherlands). The protein was dissolved in phosphate buffered 
saline (PBS) (1.37  M NaCl, 2.7  mM KCl, 10  mM Na2HPO4, 
1.8 mM KH2PO4, pH 7.4) to achieve the different concentrations 
used throughout this study. According to the manufacturer, 
the protein purity is about 80% with 3.5% moisture and 21% 
iron-saturation. Concanamycin A (ConcA), paraformaldehyde, 
cisplatin, etoposide, and β-actin antibody were purchased 
from Sigma-Aldrich. Lysosensor Green DND-189 and BCECF- 
AM [2′, 7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, 
acetoxymethyl ester] were obtained from Molecular Probes. 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) probe 
and FITC Annexin V apoptosis detection kit were acquired from 
BD Bioscience. Secondary antibody anti-mouse IgG was obtained 
from Jackson ImmunoResearch. V-ATPase C1 antibody was 
purchased from Santa Cruz Biotechnology. Vectashield mount-
ing medium was acquired from Biosystems.
cell lines and culture conditions
Human prostate cancer cell line PC-3 (CRL-1435; ATCC), human 
osteosarcoma cell line MG-63 (CRL-1427; ATCC), and human 
breast cancer cell line MDA-MB-231 (HTB-26; ATCC) were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM), sup-
plemented with 10% fetal bovine serum (FBS), both purchased 
from Biochrom—Merck Millipore, and 1% zell shield (Minerva 
Biolabs). Human fibroblast cell line BJ-5ta (CRL-4001; ATCC) 
was grown in a 4:1 mixture of DMEM and Medium 199, pur-
chased from Biochrom—Merck Millipore, supplemented with 
0.01 mg/ml hygromycin B (Sigma-Aldrich) and 10% FBS. Cells 
were maintained in culture in a 37°C incubator with a humidified 
atmosphere containing 5% CO2. For each experiment, cells were 
seeded in 6-well plates at appropriate concentrations: 1 × 105 at 
24 h and 7.5 × 104 cell/ml at 48 h for the PC-3 cell line; 9 × 104 
at 24 h and 5 × 104 cell/ml at 48 h for MG-63 and MDA-MB-231 
cell lines; and 1.5 × 105 at 24 h, 1 × 105 at 48 h, and 9 × 104 cell/ml 
at 72 h for the BJ-5ta cell line. For ECAR experiments, cells were 
seeded in XF 24-well plates at a concentration of 1 × 104 cells/
well. All the compounds under study were added to the wells only 
when cells reached at least 70% confluence.
assessment of cell Proliferation  
With cFse
Carboxyfluorescein diacetate succinimidyl ester labeling was 
performed before cell seeding. Briefly, cells were collected from 
the culture flask, washed with 1× PBS and incubated with the 
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CFSE dye (final concentration: 20  µM) for 15  min in a 37°C 
water bath. Afterward, cells were rinsed with 1× PBS, the cor-
rect amount of complete culture media to obtain the same cell 
concentration was added, and cells were plated in 6-well plates. 
After adhering for 24 h protected from light, cells were treated 
with medium (negative control), 50  µM cisplatin (MG-63 and 
MDA-MB-231 cell lines) or 60 µM etoposide (PC-3 and BJ-5ta 
cell lines) as positive controls, as well as 175 µM bLf. Cells were 
harvested and the carboxyfluorescein (CF) median fluorescence 
intensity was analyzed by flow cytometry using the FL1 channel 
0, 24, 48, and 72 h after treatment. At the moment of seeding, a 
sample from the labeled cell suspension was also collected and 
analyzed to ensure correct cell staining. All data (median values) 
were normalized to the time point 0 h, which corresponds to the 
maximum fluorescence intensity.
FiTc annexin V/Propidium iodide (aV/Pi) 
apoptosis assay
Cells were seeded in 6-well plates, two wells per condition—
negative control (without treatment), positive control (60  µM 
etoposide for PC-3 and BJ-5ta cell lines or 50 µM cisplatin for 
the MG-63 cell line), 175  µM bLf and 10  nM ConcA (used as 
positive control for V-ATPase inhibition) and incubated for 48 
and/or 72 h. Apoptosis was detected using the “FITC Annexin 
V apoptosis detection kit” according to the manufacturer’s 
instructions (BD Biosciences). After treatment, 2 × 105 cells per 
condition were harvested, rinsed with 1× PBS, resuspended in 
1× Binding Buffer (BD Pharmigen™) and incubated with 1 µl of 
AV-FITC and 1 µl of PI for 15 min in the dark. Acquisition was 
performed in a flow cytometer using the FL1 and FL4 channels, 
respectively.
phi Measurement
Measurements of pHi were performed with the pH-sensitive 
probe BCECF-AM. Cells were seeded in 6-well plates and treated 
with medium alone, 175 µM bLf or 10 nM ConcA, for 24 and/
or 48 h. After this time, cells were tripsinized and washed with 
Hank’s balanced salt solution (HBSS) (10× concentrated solution: 
1,379 mM NaCl; 53.3 mM KCl; 3.4 mM Na2HPO4-7H2O; 55.6 mM 
d-glucose and 4.4 mM KH2PO4). The pellets were resuspended in 
1× HBSS and incubated with 50 µM BCECF-AM from a stock 
solution of 161.3  µM for 30  min at 37°C protected from light. 
Samples were analyzed in a flow cytometer. The percentage of 
cells exhibiting intracellular acidification was estimated from the 
percentage of cells displaying a FL1/FL4 ratio lower than control 
cells. This ratio is independent of the probe concentration and 
exclusively dependent on the pHi.
ecar Measurement
Basal ECARs of MDA-MB-231, PC-3, MG-63, and BJ-5ta cell 
lines were determined using a Seahorse Extracellular Flux (XF24) 
Analyzer (Seahorse Bioscience). Cells were seeded into XF24 cell 
culture microplates at a cellular density of 1 × 104 cells/well in their 
normal growth media, left to adhere overnight in a humidified 
37°C incubator with 5% CO2 and then treated with 175 µM bLf 
for 24 h. In the wells corresponding to the negative control, the 
medium was changed and no treatment was added. Prior to the 
basal ECAR measurement, the growth medium was exchanged 
to a basal assay medium (DMEM 5030—Sigma-Aldrich) sup-
plemented with 4  mM glutamine and rigorously adjusted to 
pH 7.4 ± 0.1. Then, the plates were incubated for 1 h in a 37°C/
non-CO2 incubator to deplete all the glycolytic reserves. After 
ECAR measurements, the amount of protein present in each well 
was estimated using the sulforhodamine B (SRB) assay since each 
cell line has a different proliferation rate during the incubation 
period. ECAR values were normalized to the SRB absorbance 
of each well using the Wave 2.2.0 software, and plotted as the 
mean ± SD, each point representing the average of different wells.
assessment of cell Proliferation by srB 
assay
Cells were seeded in 6-well plates and incubated with 175  µM 
bLf for 24 h. Afterward, cells were fixed for 90 min at −20°C in 
ice-cold 1% acetic acid in methanol, and then incubated with 
0.5% (w/v) SRB in 1% acetic acid for 90  min at 37°C. After 
washing with 1% acetic acid and drying, protein-bound SRB was 
dissolved in 10 mM Tris pH 10.5 for 10 min at room temperature 
(RT). A sample from each condition was transferred to a 96-well 
plate and absorbance was read at 540 nm in a microplate reader 
(SpectraMax 340PC, Molecular Devices).
Protein Quantification
The soluble protein concentration was determined using the 
Bio-Rad DC protein assay (Bio-Rad Laboratories), by a modified 
Lowry method. The protein concentration of each sample was 
determined using a calibration curve obtained with solutions of 
BSA with increasing concentrations—from 5 to 0.25 mg/ml.
Western Blot
For western blot, 35 µg of protein were separated by 12.5% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis. Afterward, 
proteins were transferred onto polyvinylidene difluoride mem-
branes. Next, to avoid non-specific interactions, membranes 
were blocked in 5% non-fat milk in PBS-Tween 0.1% solution 
(1× PBST) with agitation at RT for 1–2  h. Membranes were 
then incubated overnight at 4°C with the primary antibodies, 
namely monoclonal anti-β-actin and anti-V-ATPase. Subsequently, 
membranes were incubated with secondary antibody goat anti- 
mouse IgG (1:2,000). Chemiluminescence detection was per-
formed using the ECL detection system (Millipore-Merck) in a 
ChemiDocTM XRS system (Bio-Rad).
Measurement of lysosomal acidification
Measurements of lysosomal acidification were performed with 
the Lysosensor Green DND-189 probe. Cells were grown in glass 
coverslips in 6-well plates and, after 24  h of adherence, were 
incubated with 175 µM bLf or 10 nM ConcA for 48 h. Then, the 
medium was removed and pre-warmed 1 µM probe-containing 
medium was added during 30 min, in a 37°C incubator with a 
humidified atmosphere containing 5% CO2. Next, the medium 
was replaced with fresh medium and the coverslips were mounted 
upside down in Vectashield. Samples were visualized in a Leica 
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DM 5000B (Leica Microsystems) fluorescence microscope with 
specific filter settings for Lysosensor Green. Cells from the same 
wells that were attached to the well surface and not the coverslip 
were tripsinized and analyzed by flow cytometry using the FL1 
channel. The % of cells exhibiting lysosomal acidification was 
estimated from the percentage of cells displaying a decreased 
fluorescence intensity in comparison to control cells.
Flow cytometry analysis
Flow cytometry analysis was performed in an Epic® XLTM (Beck-
manCoulter) flow cytometer equipped with an argon-iron laser 
with emission of a 488 nm beam at 15 mW. Red fluorescence was 
collected through a 560 nm short-pass dichroic, a 640 nm long-
pass, and another 670 nm long-pass filter. Green fluorescence was 
collected through a 488  nm blocking filter, 525  nm band-pass 
filter, and a 550  nm long-pass dichroic. For each experiment, 
20,000 events were evaluated for each sample and data were 
analyzed using the FlowJo 7.6 software.
statistical analysis
Experimental values are expressed as means or medians ± SD of 
at least three independent experiments. Statistical analysis was 
performed using one-way ANOVA followed by the Bonferroni 
post-test using the GraphPad Prism version 6.0.
resUlTs
The highly Metastatic Prostate cancer 
Pc-3 and the Osteosarcoma Mg-63 cell 
lines are sensitive to blf
To test whether the highly metastatic prostate cancer PC-3 and 
the osteosarcoma MG-63 cell lines were sensitive to bLf, we opti-
mized a CFSE staining protocol and used the bLf-sensitive highly 
metastatic breast cancer cell line MDA-MB-231 for comparison. 
In each cell division, the fluorescence of CFSE-stained cells is 
reduced to half of the initial fluorescence (27). Thus, when cell 
proliferation is inhibited, the expected decrease of intracellular 
fluorescence is not observed. We found that cell fluorescence 
24 h after incubation with bLf, etoposide, or cisplatin—the latter 
used as positive controls for PC-3 and MG-63, respectively—was 
not significantly different from that of untreated cells (negative 
control) (Figures 1A,B). However, after 48 and 72 h of incubation 
with bLf, as well as with the positive controls, the cell fluorescence 
decreased much slower than in the control cells (Figures 1A,B), 
indicating that cell proliferation was inhibited. The inhibition of 
cell proliferation (%) by bLf or by etoposide/cisplatin for each cell 
line was estimated and no significant differences between the three 
cancer cell lines were found (Table S1 in Supplementary Material). 
These results indicate that PC-3 and MG-63 cells exhibit a sensi-
tivity to bLf similar to that observed for the well-known apoptotic 
inducers, cisplatin or etoposide. A similar result was obtained for 
MDA-MB-231 cells that, in our previous study, showed equally 
a high sensitivity to bLf (21). In accordance with the observed 
inhibition of cell proliferation measured 48 h after exposure to 
bLf, a decrease in the cell number and changes in cell morphology 
were observed by phase contrast microscopy (Figure 1C).
blf induces apoptosis of Pc-3 and Mg-63 
cancer cell lines
The observed decrease in proliferation of bLf-treated cells can 
be due to inhibition of cell division per  se or to induction of 
cell death, specifically of apoptosis. To address this hypoth-
esis, we evaluated whether bLf was able to induce exposure 
of phosphatidylserine (PS) to the outer leaflet of the plasma 
membrane while preserving the plasma membrane integrity 
(28) using the FITC-AV/PI staining assay. Figure 2A illustrates 
representative biparametric histograms of the cells treated with 
cisplatin, etoposide, bLf, or the V-ATPase inhibitor ConcA. 
Results showed that incubation with bLf, as well as with etopo-
side or ConcA, led to exposure of PS in PC-3 cells. Indeed, the 
percentage of early (AV+/PI−) and late apoptotic cells (AV+/
PI+) for this cell line increased after 48 h of incubation with 
these compounds in comparison with untreated cells. On 
the other hand, no early or late apoptotic MG-63 cells could 
be detected after 48  h of treatment. However, we found that 
bLf, like cisplatin, induced exposure of PS 72 h after exposure, 
indicating induction of apoptosis (Figures  2A,B). Moreover, 
the percentage of AV−/PI+ cells for the two cell lines was very 
low under all treatment conditions.
blf Does not affect cell Proliferation  
nor induces cell Death of the non-
Tumorigenic cell line BJ-5ta
To assess whether bLf was selective against highly metastatic 
cancer cell lines, we next analyzed its effect on the inhibition of cell 
proliferation and induction of cell death in the non-tumorigenic 
cell line BJ-5ta. We observed that, after 72  h, bLf-treated cells 
exhibited an intracellular CFSE fluorescence decrease similar 
to that of untreated cells, indicating that cell proliferation was 
not affected and that the BJ-5ta cell line is not sensitive to bLf 
(Figures  3A–C). This was further confirmed by assessing 
apoptosis induction with the AV/PI assay. Figure 3D illustrates 
representative biparametric histograms of cells treated with bLf, 
etoposide, or ConcA for 72  h. Exposure of PS (AV+/PI− and 
AV+/PI+ cells) was only significantly different from the control 
cells after incubation with etoposide or ConcA. By contrast, these 
percentages were not significantly different between untreated 
and bLf-treated cells, suggesting that, at this time point, bLf does 
not induce apoptosis (Figure 3E).
blf induces intracellular acidification and 
inhibits the ecar in Pc-3 and Mg-63 
cancer cell lines
We next evaluated whether the observed cytotoxic effects of 
bLf could be associated with an intracellular acidification and a 
decrease in the capacity of PC-3 and MG-63 cancer cells to acidify 
the extracellular medium due to the inhibition of V-ATPase by 
bLf. To this end, pHi measurements were performed using the 
pH-sensitive probe BCECF-AM. This probe rapidly diffuses 
into cells and is cleaved by intracellular esterases to its unsteri-
fied form, which emits fluorescence according to the pHi (29). 
The results are expressed as the percentage of cells that exhibit 
FigUre 1 | Bovine lactoferrin (bLf) inhibits proliferation of highly metastatic cancer cell lines. (a) Representative histograms of cell proliferation analysis with 
carboxyfluorescein diacetate succinimidyl ester probe of the different conditions after 0, 24, 48, and 72 h exposure to bLf in the three indicated cell lines. Unexposed 
cells were used as a negative control and 50 µM cisplatin (for MG-63 and MDA-MB-231 cell lines) or 60 µM etoposide (for PC-3 cells) were used as positive 
controls. (B) Quantification of the carboxyfluorescein median fluorescence intensity values normalized to T0 after 24, 48, and 72 h of exposure. Values represent 
median ± SD of three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0,001 compared with negative control of each time point and #P < 0.05; 
##P < 0.01, and ###P < 0,001 compared with 24 h. (c) Representative images of cell cultures after 48 h of treatment with bLf, cisplatin or etoposide in PC-3, MG-63, 
and MDA-MB-231 cell lines (10× phase contrast).
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a decrease in the ratio of FL1/FL4 (linear cursor), reflecting an 
intracellular acidification in comparison with untreated cells 
(negative control). Figure 4A shows representative histograms of 
cells incubated in the absence or presence of 175 µM of bLf or 
10 nM ConcA for 48 h. We found an increase in the percentage 
of PC-3 and MG-63 cells exhibiting intracellular acidification 
after 48 h of treatment with bLf or ConcA, in comparison with 
untreated cells (Figures 4A,B). By contrast, the bLf or ConcA-
treated BJ-5ta cells did not exhibit alterations of pHi, indicating a 
similar behavior to untreated cells.
Basal ECAR measurements were performed using an XF 
Extracellular Flux Analyzer, which allows measuring the non-
glycolytic acidification often named basal ECAR. Before record-
ing the ECAR, 24 h-treated cells were transferred to a glucose-free 
medium and incubated for 1 h in a non-CO2 incubator to exhaust 
their glycolytic reserves. During this period, the production and 
efflux of lactic acid occurs, which ensures that the subsequent 
measurement of proton extrusion only reflects the extracellular 
acidification mediated by the plasmalemmal V-ATPase. Though 
not statistically significant, results showed that a 24-h treatment 
FigUre 2 | Bovine lactoferrin (bLf) induces cell death of the highly metastatic cancer cell lines PC-3 and MG-63. (a) Exposure of phosphatidylserine induced by bLf 
or concanamycin A (ConcA) monitored by AV-FITC/PI staining. Representative histograms of cells untreated (negative control) or treated during 48 h (for PC-3) and 
72 h (for MG-63) with 175 µM bLf or 10 nM ConcA, or with 50 µM cisplatin or 60 µM etoposide (used as positive controls, for MG-63 and PC-3 cells, respectively). 
(B) Quantitative analysis of the AV/PI assays in panel (a). Values represent mean ± SD of three independent experiments, *P < 0.05 and ***P < 0.001 when 
compared with negative control cells.
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with 175 µM bLf inhibited the basal ECAR of the prostate PC-3 
and osteosarcoma MG-63 cancer cells as well of the breast cancer 
cells MDA-MB-231, while had no effect on the non-tumorigenic 
cells (Figure 4C).
The high sensitivity of Pc-3 and Mg-63 
cells to blf is associated With high 
levels of V-aTPase expression
In order to determine a possible relationship between the different 
sensitivity of highly metastatic cancer cells and non-tumorigenic 
cells to bLf and differences in V-ATPase expression, the levels 
of this proton pump were evaluated by western blot (Figure 5). 
Results showed that PC-3 and MG-63 cells display higher levels 
of V-ATPase in comparison with the non-tumorigenic cell line 
BJ-5ta. We also observed that the total amount of the V-ATPase is 
higher in the three highly metastatic cancer cells than in the non-
tumorigenic cell line BJ-5ta, which is in agreement with previous 
results showing that in these cells V-ATPase is highly abundant 
in the plasma membrane (23–25).
blf inhibits lysosomal acidification in 
Pc-3, Mg-63, and MDa-MB-231 cancer 
cell lines but not in the non-Tumorigenic 
cell line BJ-5ta
Different studies showed that compounds with a similar effect 
to the well-established V-ATPase inhibitors bafilomycin A1 
(BafA1) and ConcA prevent lysosomal acidification in mam-
malian cells (30). We therefore evaluated whether exposure to 
FigUre 3 | Bovine lactoferrin (bLf) does not affect the cell proliferation nor induces cell death on the non-tumorigenic cell line BJ-5ta. (a) Representative histograms 
of cell proliferation analysis with carboxyfluorescein diacetate succinimidyl ester probe after 0, 24, 48, and 72 h exposure to bLf. Unexposed cells were used as a 
negative control. (B) Quantification of the carboxyfluorescein median fluorescence values normalized to T0 after 24, 48, and 72 h of exposure. Values represent 
median ± SD of three independent experiments. ns, non-significant. (c) Representative images of BJ-5ta cell cultures after 48 h of treatment with bLf and etoposide 
(10× phase contrast). (D) Exposure of phosphatidylserine induced by bLf or concanamycin A (ConcA) was monitored by AV-FITC/PI staining. Representative 
histograms of untreated cells (negative control) or treated during 72 h with 175 µM bLf, 10 nM ConcA, or with 60 µM etoposide (used as positive control).  
(e) Quantitative analysis of the AV/PI assays in panel (D). Values represent mean ± SD of three independent experiments, **P < 0.01 and ***P < 0.001 when 
compared with negative control cells.
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bLf, as well as to ConcA, could inhibit the lysosomal V-ATPase 
in the cell lines under study. For this purpose, cells were stained 
with Lysosensor Green, a fluorescent dye that specifically stains 
acidic organelles such as lysosomes, and has a pH-dependent 
fluorescence intensity that decreases upon alkalinization of 
acidic compartments. Flow cytometric analyses of the untreated 
cells of the three highly metastatic cancer cell lines revealed a 
more acidic lysosomal compartment in comparison to the non-
tumoral cells. Indeed, the median intensity fluorescence values 
of these cells were threefold to fourfold higher than BJ-5ta cells 
(Figures  6A,B). This strongly suggests that V-ATPase is more 
abundant (or more active) in the lysosomal membrane of highly 
metastatic cancer cells. We also observed by fluorescence micros-
copy that the three highly metastatic cancer cell lines exhibited a 
decrease in fluorescence intensity 48 h after treatment with bLf 
or ConcA, in contrast with untreated cells (negative control) 
(Figure 6C). On the other hand, bLf has no effect against BJ-5ta 
cell line, in contrast with ConcA that decreased the fluorescence 
intensity. These results were further confirmed by monitoring the 
percentage of Lysosensor-loaded cells displaying lower median 
fluorescence intensity values by flow cytometry (Figures 6A,D). 
Accordingly, bLf induced an increase in the percentage of cells 
with lower fluorescence intensity in the highly metastatic cancer 
cells but not in the non-tumorigenic cells while ConcA decreased 
the fluorescence in all cell lines (Figures 6C,D).
DiscUssiOn
Prostate cancer and osteosarcoma are incident and relevant causes 
of human deaths due to different factors. The rising trends in pros-
tate cancer incidence and mortality have been largely attributable 
to the widespread availability of prostate-specific antigen tests 
in the late 1980s and hence to the increased detection of latent 
disease (31). In the case of osteosarcoma, there is an increased 
risk of developing childhood cancer following radiotherapy or 
treatment with alkylating agents (2). Therefore, the finding and 
characterization of novel efficient drugs is a current challenge. 
Since bLf is a natural anticancer compound that has no second-
ary effects and reduced risk of chemoresistance, we addressed 
whether it may be exploited in the therapy of these cancers. 
FigUre 5 | V-ATPase expression levels in highly metastatic prostate PC-3 and osteosarcoma MG-63 cancer cell lines in comparison with the highly metastatic 
breast cancer cell line MDA-MB-231 and the non-tumorigenic cell line BJ-5ta. (a) Representative western blot images of V-ATPase expression in each cell line using 
35 µg of protein extracts in each lane. β-actin was used as a loading control. (B) Quantification of the levels of V-ATPase expression in the four cell lines normalized 
to the levels of β-actin. The values represent three independent assays.
FigUre 4 | Effect of bovine lactoferrin (bLf) on the intracellular acidification and basal extracellular acidification rates (ECARs) in the highly metastatic cancer cell 
lines PC-3 and MG-63 and in the non-tumorigenic cell line BJ-5ta. (a) Representative histograms of the percentage of BCECF-AM-loaded cells displaying 
intracellular acidification assessed through the decrease of FL1/FL4 median fluorescence intensity ratio in comparison to negative control cells at 48 h.  
(B) Quantification of the percentage of cells displaying intracellular acidification after treatment with 175 µM bLf or 10 nM concanamycin A (ConcA), for 24 and 48 h 
(identified under the cursor on ratio). Values represent the mean ± SD of three independent experiments; ns, non-significant, *P < 0.05 and **P < 0.01 compared 
with the negative control of each cell line. (c) Basal ECARs of cells after 24 h incubation in the absence (negative control) or presence of 175 µM bLf. The bLf 
sensitive highly metastatic breast cancer cell line was used for comparison. ECAR values are normalized to the negative control cells of each cell line. Results are 
expressed in mpH per minute per sulforhodamine B (SRB) absorbance at 540 nm. Values represent the mean ± SD of three independent experiments.
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For this purpose, we determined the activity of bLf against the 
highly metastatic prostate cancer (PC-3) and osteosarcoma 
(MG-63) cell lines. In our previous study, we tested different bLf 
concentrations—50, 125, and 175 µM and found that the effect 
was more evident with 175  µM bLf (21). In this sense, in this 
study, we only used this concentration. Herein, we show that 
PC-3 and MG-63 cells are highly sensitive to bLf, regarding 
both inhibition of cell proliferation, induction of apoptosis and 
intracellular acidification. Notably, these cell lines that have high 
sensitivity to bLf have V-ATPase localized at the plasma membrane 
(21, 23–25). We also show that bLf tends to decrease the basal 
ECAR, which is mainly maintained by V-ATPase in highly 
metastatic cancer cells (23). By contrast, none of these effects were 
detected in the non-tumorigenic BJ-5ta cells. Thus, exposure 
of V-ATPase at the plasma membrane and its inhibition in the 
prostate cancer and osteosarcoma cells seems to determine their 
sensitivity to bLf, as previously shown for the highly metastatic 
breast cancer cell lines (21).
FigUre 6 | Continued
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FigUre 6 | Bovine lactoferrin (bLf) inhibits lysosomal acidification in the highly metastatic cancer cell lines but not in the non-tumorigenic cell line. (a) Representative 
histograms of the % of Lysosensor-loaded MDA-MB-231, PC-3, MG-63, and BJ-5ta cells displaying lower FL1 mean fluorescence intensity (FL1-cursor) after 48 h 
treatment with 175 µM bLf or 10 nM ConcA. (B) Mean fluorescence intensity values of the four cell lines before treatment with bLf. Values represent the mean ± SD 
of three independent experiments; **P < 0.01 and ***P < 0.001 compared with BJ-5ta cells. (c) Representative fluorescence microscopy images of the cells stained 
with Lysosensor Green DND-189 upon 48 h of treatment with 175 µM bLf or 10 nM ConcA. The probe stains acidic compartments mainly lysosomes. (D) Mean % 
values of cells treated under the same conditions displaying lower fluorescence intensity in comparison with untreated cells. Values represent the mean ± SD of 
three independent experiments; *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the negative control of each cell line.
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To further support that V-ATPase is a molecular target of bLf 
in PC-3 and MG-63 cancer cells, we examined a possible relation 
between cell sensitivity and the levels of V-ATPase as compared 
with the bLf-sensitive breast cancer MDA-MB-231 and to the 
bLf-insensitive non-tumorigenic BJ-5ta cell lines. We show that 
the higher sensitivity of the three highly metastatic cell lines to bLf 
is associated with higher levels of V-ATPase in comparison with 
the non-tumorigenic cell line. Accordingly, other authors have 
also reported that cancer cells have increased levels of V-ATPase 
(32, 33). These results support the notion that bLf targets the 
V-ATPase at the plasma membrane, hindering its activity and 
decreasing the TME acidity, and in this way likely limit tumor 
progression and metastasis.
It was reported that PC-3 cells undergo apoptosis when exposed 
to other compounds like the chemotherapeutic agents salinomycin 
(34) and monensin (35), associated with exposure of PS. Also, other 
studies with the osteosarcoma MG-63 cell line showed apoptosis 
induction through exposure of PS by treatment with berberine (36) 
and ascorbic acid (37). Herein, we demonstrate that bLf-induced 
inhibition of cell proliferation in the highly metastatic cancer cell 
lines PC-3 and MG-63 is associated with an increase in AV+/
PI− staining. Similarly, we recently showed that cell proliferation 
inhibition of the highly metastatic breast cancer cells Hs 578T and 
MDA-MB-231 by bLf was accompanied by induction of cell death 
associated with exposure of PS (21). Other authors found that 
the non-invasive breast cancer cell line MCF-7, sensitive to bLf, 
also displays this apoptotic marker in response to bLf treatment 
(8, 9). Furthermore, in contrast to ConcA or etoposide-treated 
cells, the non-tumorigenic cells BJ-5ta do not die even 72 h after 
exposure. This observation together with the lack of inhibition of 
cell proliferation is in good agreement with their resistance to bLf. 
Likewise, we also did not detect early and late apoptotic cells for the 
non-tumorigenic breast cell line MCF-10-2A (21).
As referred above, BafA1 and ConcA interfere with V-ATPase 
proton pumping activity and affect lysosomal acidification in 
mammalian cells (30). Interestingly, a recent study reported the 
sensitivity of the human breast cancer cells MDA-MB-231 to the 
proton pump inhibitor lansoprazole (38). These authors showed 
that this compound induces apoptosis through its ability to sup-
press proton pumping activity and induce lysosomal alkaliniza-
tion. We therefore evaluated whether exposure to bLf, as well as 
to ConcA, could inhibit the lysosomal V-ATPase in the cell lines 
under study. We show that, as described for lansoprazole in breast 
cancer cell lines, bLf induces lysosomal pH perturbations similarly 
to ConcA, in the highly metastatic cancer cell lines PC-3, MG-63, 
and MDA-MB-231. However, the BJ-5ta cells treated with bLf, but 
not with ConcA, exhibit a behavior identical to that of untreated 
cells. It is noteworthy that PC-3, MG-63, and MDA-MB-231 cells 
show lysosomes with lower pH than BJ-5ta cells. This is likely 
due to a higher V-ATPase content at the lysosomal membrane, 
which would explain the relation between lysosomal dysfunction 
and sensitivity to bLf. This perturbation in lysosomal pH is much 
likely due to the intracellular acidification mediated by inhibition 
of the plasmalemmal V-ATPase or possibly by internalized bLf. 
Indeed, though there is no data in the literature regarding inter-
nalization of bLf in the prostate PC-3 and osteosarcoma MG-63 
cell lines, in the case of MDA-MB-231 cells the internalization 
of a small amount of bLf was reported (17). In line with this 
hypothesis, we had previously demonstrate that bLf, like the pro-
ton pump inhibitors ConcA and BafA1, inhibits V-ATPase proton 
pumping and hydrolytic activities in crude membrane fractions 
and isolated lysosomes (21). Altogether, these data support the 
notion that the selectivity of bLf relies not only in the intracellular 
acidification caused by inhibition of plasmalemmal V-ATPase 
but also in the lysosomal V-ATPase dysfunction, which in this 
way amplifies its cytotoxic effects (Figure 7). These mechanistic 
insights further reinforce the bLf great advantage over other con-
ventional V-ATPase inhibitors used as anticancer agents, namely 
the absence of secondary effects.
In another highly metastatic breast cancer cell line (4T1), 
known to exhibit V-ATPase at the plasma membrane, the com-
bined treatment of Lf and tamoxifen suppresses the dissemination 
of lung and liver tumor metastases (39). Also, Lf administration 
significantly inhibits liver and lung metastasis produced by 
L5178Y-ML25 lymphoma cells and B16-BL6 melanoma cells, 
respectively (40). The recognized high levels of V-ATPase in 
cancer cells (32, 33) likely explains the anti-metastatic role of 
Lf against these other types of highly metastatic cancer cells. 
However, it would be interesting in the future to assess whether 
Lf induces lysosomal dysfunction in L5178Y-ML25 lymphoma 
and B16-BL6 melanoma cells, which also expose V-ATPase at the 
plasma membrane.
A recent study asserts that the abnormalities of extracellular 
acidification along with intracellular alkalinization of all types of 
solid tumors and leukemic cells appear to be a specific hallmark 
of malignancy (41). Attempts to induce intracellular acidification 
using proton transport inhibitors and other intracellular acidi-
fiers, is thus becoming a new therapeutic strategy in cancer treat-
ment. Notably, our finding that bLf acts as a specific inhibitor of 
V-ATPase at the plasma membrane of different highly metastatic 
cancer cells, while exerting no effect on non-tumorigenic cells 
is aligned with this novel concept. Besides, being bLf a natural 
compound means that its clinical usage surpasses multidrug 
resistance, which is a severe problem of current cancer therapies. 
Moreover, the dose used in this study is in the range used in 
several in vivo studies (42), therefore it is clinically relevant and 
it can be used for further analysis in in vivo models. Finally, as 
bLf is a commercially available non-toxic and low-cost dietary 
FigUre 7 | Working model for the molecular mechanism underlying the anticancer activity of bovine lactoferrin (bLf). The exposure of highly metastatic cancer cells 
to bLf leads to the inhibition of plasmalemmal V-ATPase proton pumping activity and subsequent extracellular alkalization, intracellular acidification, inhibition of cell 
proliferation, and induction of apoptosis. The observed lysosomal dysfunction is possibly due to lysosomal V-ATPase inhibition. By contrast, the non-tumorigenic 
cells, which do not have plasmalemmal V-ATPase and express lower levels of this protein, are resistant to bLf.
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natural protein, the finding of V-ATPase as a selective and com-
mon molecular target of highly metastatic cancers brings novel 
important data for further in  vitro and in  vivo researches on 
the anticancer activity of bLf, and will ultimately contribute to 
its safer and more rational application as a nutraceutical in the 
human therapy of highly metastatic cancers.
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